Antiproliferative Effect of 1-Deamino-8-
            <scp>D</scp>
            -Arginine Vasopressin Analogs on Human Breast Cancer Cells

Iannucci, Nancy B.; Ripoll, Giselle Vanina; Garona, Juan; Cascone, Osvaldo; Ciccia, G.; Gomez, Daniel E.; Alonso, Daniel F.

doi:10.4155/fmc.11.152

Cited by 30 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AVP has been shown to induce a dose-dependent (from 1 nM) and time-persistent increase of tumor cell proliferation. V2 receptors are present in human breast cancer (47), cervical cancer (85), and lung cancer (95) cells and in corticotrophinomas, with V2Rs varying greatly, being lower in macroadenomas than in microadenomas (126). An abnormal truncated V2R was also detected in MCF-7 cells, although it appeared to be nonfunctional (87)(88)(89).…”

Section: Distribution and Function Of V2rsmentioning

confidence: 99%

See 1 more Smart Citation

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Juul

Bichet

Nielsen

et al. 2014

American Journal of Physiology-Renal Physiology

124

View full text Add to dashboard Cite

Juul KV, Bichet DG, Nielsen S, Nørgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol 306: F931-F940, 2014. First published March 5, 2014 doi:10.1152/ajprenal.00604.2013.-The arginine vasopressin (AVP) type 2 receptor (V2R) is unique among AVP receptor subtypes in signaling through cAMP. Its key function is in the kidneys, facilitating the urine concentrating mechanism through the AVP/V2 type receptor/aquaporin 2 system in the medullary and cortical collecting ducts. Recent clinical and research observations strongly support the existence of an extrarenal V2R. The clinical importance of the extrarenal V2R spans widely from stimulation of coagulation factor in the endothelium to as yet untested potential therapeutic targets. These include V2R-regulated membranous fluid turnover in the inner ear, V2R-regulated mitogensis and apoptosis in certain tumor tissues, and numerous other cell types where the physiological role of V2Rs still requires further research. Here, we review current evidence on the physiological and pathophysiological functions of renal and extrarenal V2Rs. These functions of V2R are important, not only in rare diseases with loss or gain of function of V2R but also in relation to the recent use of nonpeptide V2R antagonists to treat hyponatremia and possibly retard the growth of cysts and development of renal failure in autosomal dominant polycystic kidney disease. The main functions of V2R in principal cells of the collecting duct are water, salt, and urea transport by modifying the trafficking of aquaporin 2, epithelial Na ϩ channels, and urea transporters and vasodilation and stimulation of coagulation factor properties, mainly seen with pharmacological doses of 1-desamino-8-D-AVP. The AVPR2 gene is located on the X chromosome, in a region with high probability of escape from inactivation; this may lead to phenotypic sex differences, with females expressing higher levels of transcript than males. vasopressin V 2 receptor; arginine vasopressin V2 receptor; arginine vasopressin; desmopressin; extrarenal vasopressin V 2 receptor THE PURPOSE OF THIS REPORT is to review current evidence on the physiological and pathophysiogical functions of renal and extrarenal arginine vasopressin (AVP) type 2 receptors, referred to as V2Rs (Fig. 1).AVP is an important neurohypophyseal nonapeptide that, via its three receptor types, is primarily responsible for regulating osmotic homeostasis of body fluids, volume homeostasis, and vasoconstriction in addition to an array of central functions such as memory and learning (17,29). In addition to these endocrine functions, AVP also contributes to regulating mitogenesis, cell survival, and death (apoptosis) (77).AVP is released from its storage site in the posterior pituitary (Fig. 2) by highly sensitive osmotic stimuli, specifically by a Ͻ1-2% increase in plasma osmolarity, as originally detailed in the 1940s through classic research by Prof. E. B. Verney (125). AVP release may also ...

show abstract

Section: Distribution and Function Of V2rsmentioning

confidence: 99%

“…The presence of all AVP receptor subtypes, but particularly V2R, has been reported in transformed epithelial cells (86,89). V2R is present in a wide panel of human tumor cell lines, including human breast cancer cells (47), cervical cancer (85), lung cancer (95), and in corticotrophinomas (126).…”

mentioning

confidence: 99%

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Juul

Bichet

Nielsen

et al. 2014

American Journal of Physiology-Renal Physiology

124

View full text Add to dashboard Cite

show abstract

“…Interestingly, DDAVP inhibited experimental lung metastasis of mammary tumor cells in a mouse model (Alonso et al, 1999). In human breast cancer cell lines, DDAVP exhibits moderate antiproliferative effects (Iannucci et al, 2011). Concerning studies on canines, Hermo et al, (2008 and carried out two clinical trials in bitches with MMT to test the efficacy of perioperative administration of DDAVP after mastectomy.…”

Section: Conventional Therapies and New Treatment Strategiesmentioning

confidence: 99%

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

2016

View full text Add to dashboard Cite

Mammary tumors are the most common neoplasm in the female dog, with a median age of appearance between 9 and 11 years. They may appear as single or multiple nodules, and posterior mammary glands are more frequently affected than anterior glands. Both benign and malignant tumors may occur in the dog, and according to histological criteria, approximately 50% of the tumors are malignant. Mammary gland tumors tend to be heterogeneous in their pathological characteristics and clinical behavior. Different hormones and growth factors play a key role in the development of this neoplasm, however, the mechanism by which they influence tumor growth and their possible prognostic value are still under study. Besides, new therapeutic options for each particular tumor type are being developed. The aim of this article is to review pathological, prognostic and therapeutic aspects of canine mammary neoplasms.

show abstract

“…Interestingly, in a mouse model of breast cancer, DDAVP inhibited lung colonization by neoplastic cells (24). Since then, a number of studies have shown that this peptide seems to have antimetastatic and antiproliferative effects, both in mouse models of breast cancer and in different breast cancer cell lines (25, 26). Furthermore, a veterinary clinical trial has demonstrated that the perioperative administration of DDAVP increases the disease free and overall survival time in surgically treated bitches with mammary cancer of various histological types (27).…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative Effects of Oxytocin and Desmopressin on Canine Mammary Cancer Cells

et al. 2016

View full text Add to dashboard Cite

Neoplasms of the mammary gland represent the most frequent tumor type in the female dog, and according to the histologic criteria, approximately 50% of them are malignant. In the most aggressive cases of mammary cancer, surgery is not enough to warrant a favorable outcome, and adjuvant therapies are needed to improve the patient’s overall survival. The aim of the present study was to evaluate the effects of two peptides on proliferation of a canine mammary cancer cell line derived from a simple carcinoma. The cell line CMT-U27 was grown in 96-well plates, at two cell densities (4 × 103 and 8 × 103 cells/well). Cultures were treated with oxytocin (OT) or desmopressin at five concentrations (10, 50, 100, 500, and 1000 nM). After 72 h of incubation, cell proliferation was determined by the MTT assay. Results showed that with 4 × 103 cells/well, OT at 50, 500, and 1000 nM was growth inhibitory for the cells, being statistically significant at 1000 nM. On the contrary, no antiproliferative effect was observed with 10 or 100 nM. At 8 × 103 cells/well, OT showed a significant antiproliferative effect only with the highest concentration (1000 nM). Desmopressin at 4 × 103 cells/well decreased cell viability at concentrations of 50, 100, 500, and 1000 nM (statistically significant with the highest concentration), while no effect was observed with 10 nM. With 8 × 103 cells/well, this peptide reduced cell growth at 100, 500, and 1000 nM. In conclusion, we suggest that these peptides may be potential and promising compounds for the treatment of dogs with simple carcinomas of the mammary gland. In vivo studies are required to confirm this hypothesis.

show abstract

Antiproliferative Effect of 1-Deamino-8- D -Arginine Vasopressin Analogs on Human Breast Cancer Cells

Abstract: Preclinical evaluation of the anti-tumor activity of [V(4)Q(5)]dDAVP in animal models is warranted.

Cited by 30 publications

References 24 publications

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

Antiproliferative Effects of Oxytocin and Desmopressin on Canine Mammary Cancer Cells

Contact Info

Product

Resources

About